Download presentation
Presentation is loading. Please wait.
Published bySandrine Lambert Modified over 5 years ago
1
Ibrutinib Treatment of CLL: The Cancer Fights Back
Ryan M. Young, Louis M. Staudt Cancer Cell Volume 26, Issue 1, Pages (July 2014) DOI: /j.ccr Copyright © 2014 Elsevier Inc. Terms and Conditions
2
Figure 1 B Cell Receptor Signaling in Malignant B Cells
Chronic active BCR signaling is shown. Ibrutinib is shown to inhibit BTK. Red asterisks denote signaling effectors that are the target of ibrutinib resistance mutations in CLL patients. Cancer Cell , 11-13DOI: ( /j.ccr ) Copyright © 2014 Elsevier Inc. Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.